Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota. (June 2018)

• Record Type: Journal Article
• Authors: Kumar, Manoj; Mathur, Tarun; Joshi, Vattan; Upadhyay, Dilip J.; Inoue, Shin-ichi; Masuda, Nobuhisa
• Is Part Of: Anaerobe. Volume 51(2018)
• Page Start: 120
• Page End: 123
• Publication Date: 2018-06
• Subjects: Clostridium difficile -- Microbiota; Anaerobic infections -- Periodicals; Anaerobic bacteria -- Periodicals; Bacterial diseases -- Periodicals; Computer network resources; Anaerobic protozoa -- Periodicals; 579.3
• DOI: 10.1016/j.anaerobe.2018.04.017
• Languages: English
• ISSNs: 1075-9964

Abstract

Abstract: DS-2969b, a novel GyrB inhibitor, transiently and reversibly altered the counts of limited intestinal microbiota at around 10 μg/g of faecal levels in rats and monkeys. Considering the high activity of DS-2969b against Clostridium difficile, 10 μg/g of faecal levels would be sufficient for clearing C. difficile from the intestine. Highlights: DS-2969b is being developed for Clostridium difficile treatment. DS-2969b has potent activity against C. difficile epidemic NAP1/027 strains. The impact of DS-2969b on microbiota and efficacious fecal level was evaluated. DS-2969b showed a transiently effect on microbiota at ∼10 μg/g of fecal level.